Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status Prescription; Discontinued
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.001251%
Disturbance in attention19.21.02.002; 17.03.03.001--
Diverticulitis07.10.02.001; 11.01.07.0030.001332%Not Available
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.007--
Dizziness postural24.06.02.008; 02.01.02.005; 17.02.05.0040.000533%Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dry skin23.03.03.0010.006127%
Duodenal perforation07.04.02.0010.000139%
Duodenal ulcer07.04.02.0020.001066%
Dysaesthesia17.02.06.0030.000533%
Dysarthria17.02.08.001; 19.19.03.001--
Dysgeusia17.02.07.003; 07.14.03.0010.029305%
Dyspepsia07.01.02.0010.010656%
Dysphagia07.01.06.0030.009591%
Dysphonia19.19.03.002; 17.02.08.004; 22.02.05.0050.006927%
Dyspnoea02.01.03.002; 22.02.01.0040.032236%
Dyspnoea at rest22.02.01.025; 02.01.03.0070.000799%Not Available
Dyspnoea exertional22.02.01.005; 02.01.03.0030.001865%Not Available
Dysuria20.02.02.002--
Ear infection11.01.05.001; 04.03.01.006--Not Available
Eating disorder19.09.01.008; 14.03.01.008--Not Available
Electrocardiogram QT prolonged13.14.05.004--
Electrocardiogram T wave inversion13.14.05.0070.000533%Not Available
Electrolyte imbalance14.05.01.0020.001066%Not Available
Encephalitis11.01.03.008; 17.06.05.0010.000139%
Encephalopathy17.13.02.001--
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 28 Pages